Optimal Care for Patients with Anaplastic Lymphoma Kinase (ALK)–Positive Non–Small Cell Lung Cancer: A Review on the Role and Utility of ALK Inhibitors

類似資料

• Anaplastic lymphoma kinase (ALK) inhibitors for second-line therapy of non-small cell lung cancer
  著者:: Berghmans, Thierry, 等
  出版事項: (2012)
• Development of anaplastic lymphoma kinase (ALK) inhibitors and molecular diagnosis in ALK rearrangement-positive lung cancer
  著者:: Iwama, Eiji, 等
  出版事項: (2014)
• Current evidence in support of the second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor alectinib for the treatment of non-small cell lung cancer positive for ALK translocation
  著者:: Hayashi, Hidetoshi, 等
  出版事項: (2016)
• ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Small-Cell Lung Cancer
  著者:: Shaw, Alice T., 等
  出版事項: (2019)
• The efficacy of immune checkpoint inhibitors in anaplastic lymphoma kinase‐positive non‐small cell lung cancer
  著者:: Ja Yoon Heo, 等
  出版事項: (2019-11-01)